Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Other financing activities (2020 - 2024)

Historic Other financing activities for RxSight (RXST) over the last 5 years, with Q3 2024 value amounting to $391000.0.

  • RxSight's Other financing activities fell 6086.09% to $391000.0 in Q3 2024 from the same period last year, while for Sep 2025 it was $768000.0, marking a year-over-year decrease of 141.21%. This contributed to the annual value of $768000.0 for FY2024, which is 6563.76% down from last year.
  • According to the latest figures from Q3 2024, RxSight's Other financing activities is $391000.0, which was down 6086.09% from $377000.0 recorded in Q2 2024.
  • RxSight's Other financing activities' 5-year high stood at $999000.0 during Q3 2023, with a 5-year trough of -$110000.0 in Q4 2021.
  • Its 5-year average for Other financing activities is $339153.8, with a median of $230000.0 in 2023.
  • Its Other financing activities has fluctuated over the past 5 years, first tumbled by 11601.16% in 2021, then surged by 60070.42% in 2023.
  • RxSight's Other financing activities (Quarter) stood at $687000.0 in 2020, then tumbled by 116.01% to -$110000.0 in 2021, then surged by 365.45% to $292000.0 in 2022, then crashed by 96.23% to $11000.0 in 2023, then skyrocketed by 3454.55% to $391000.0 in 2024.
  • Its Other financing activities stands at $391000.0 for Q3 2024, versus $377000.0 for Q2 2024 and $11000.0 for Q4 2023.